Basic Pharma

• Basic Pharma, a Netherlands-based pharmaceutical developer and full-service contract development and manufacturing organisation (CDMO), has been acquired by SHS Capital
• The company is a leading CDMO focused on prescription and over-the-counter pharmaceuticals across liquid and semi-solid dosage forms
• With SHS Capital, Basic Pharma has found a complementary partner bringing deep sector expertise and an international network to accelerate its long-term growth ambitions
• The transaction marks a successful exit by founder and CEO Bob Kool, Brightlands Ventures and Particon. Bob Kool will reinvest alongside SHS Capital and continue to support the company in its next phase of growth
• Van Lanschot Kempen acted as Financial Adviser to Basic Pharma and its shareholders in the transaction, and managed a competitive process with (international) financial sponsors and strategic buyers, delivering a strong outcome for all stakeholders
  
  "Van Lanschot Kempen helped shape the equity story to position Basic Pharma’s integrated business model, broad capabilities and growth potential. Their hands-on support throughout the process and access to a broad universe of international buyers has resulted in a very successful transaction to SHS”  
  Bob Kool, CEO and Founder at Basic Pharma
  
  “Basic Pharma is exactly the type of company we look for: a specialized European healthcare champion with a differentiated business model, proprietary dossiers and significant untapped international potential,” says Dr. Cornelius Maas, Partner at SHS Capital. “We look forward to supporting the team in the next phase of growth, organically and through selective acquisitions.” 
  Dr. Cornelius Maas, Partner at SHS Capital

Basic Pharma is a Netherlands-based pharmaceutical developer and full-service CDMO with end-to-end capabilities across the development, registration, and manufacturing of liquid and semi-solid dosage forms. The company is a leading European manufacturer of nasal sprays and combines its expertise with a growing suite of regulatory affairs, pharmacovigilance and quality services for third parties.

Van Lanschot Kempen’s Life Science & Healthcare franchise has executed on a strong track record of successful transactions. Selected recent transactions include:

• Lead Manager in the USD 920 million Public Offering by Abivax
• Exclusive Financial Advisor to Valerio Therapeutics in the proposed acquisition of Etherna Immunotherapies
• Joint Bookrunner in the up to EUR 84 million Capital Increase by Valneva
• Joint Bookrunner in the SEK 350 million Capital Increase by Egetis Therapeutics
• Joint Book-Running Manager in the USD 200 million IPO by Agomab Therapeutics
• Sole Global Coordinator and Joint Bookrunner in the €105 million Capital Increase by Transgene
• Co-manager in the USD 110 million financing by Oculis
• Co-Lead Manager in the USD 149 million Public Offering by enGene
• Joint Bookrunner in the SEK 672 million Capital Increase by Hansa BioPharma
• Joint Bookrunner in the USD 345 million Capital Increase by uniQure
• Joint Bookrunner in the SEK 720 million sale of existing shares by BioArctic shareholders
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris
• Financial Advisor in the €37.5 million venture debt financing by MaaT Pharma